文献速递骨质疏松与钙磷/甲状旁腺

利福平诱导CYP3A4:CYP24A1突变患者维生素D失活的替代途径

CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

两名CYP24A1突变所致特发性婴儿高钙血症患者接受每日利福平(10 mg/kg/d,最大600 mg)治疗,监测长达13个月。治疗前两名患者均有高钙血症、高钙尿症、肾钙质沉着症伴血清1,25-二羟维生素D3升高和PTH受抑。利福平耐受良好,使所有临床和生化指标正常化或改善。

要点

  • 利福平是CYP3A4强诱导剂,在CYP24A1功能缺失患者中使所有临床和生化指标正常化或改善。
  • 两名CYP24A1突变特发性婴儿高钙血症患者接受每日利福平10 mg/kg/d(最大600 mg)治疗。
  • 治疗前两名患者均有高钙血症、高钙尿症、肾钙质沉着症伴血清1,25-二羟维生素D3升高和PTH受抑。

核心结论

  • 这些观察提示利福平诱导的CYP3A4过表达为缺乏CYP24A1功能的患者提供了维生素D代谢物失活的替代途径。

研究设计与样本

  • 对两名CYP24A1突变所致特发性婴儿高钙血症患者给予每日利福平(10 mg/kg/d,最大600 mg)治疗,监测长达13个月。

主要发现

  • 治疗前两名患者均有高钙血症、高钙尿症和肾钙质沉着症,伴血清1,25-二羟维生素D3升高和血清PTH受抑。
  • 每日利福平治疗耐受良好,使所有临床和生化指标正常化或改善。

关键数值与推荐

  • 利福平剂量为10 mg/kg/d,最大600 mg,每日给药。

临床怎么用

  • 原作者认为利福平诱导的CYP3A4过表达可能为CYP24A1功能缺失患者提供维生素D代谢物失活的替代途径。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: The P450 enzyme CYP24A1 is the principal inactivator of vitamin D metabolites. Biallelic loss-of-function mutations in CYP24A1 are associated with elevated serum levels of 1,25-dihydroxyvitamin D3 with consequent hypercalcemia and hypercalciuria and represent the most common form of idiopathic infantile hypercalcemia (IIH). Current management strategies for this condition include a low-calcium diet, reduced dietary vitamin D intake, and limited sunlight exposure. CYP3A4 is a P450 enzyme that inactivates many drugs and xenobiotics and may represent an alternative pathway for inactivation of vitamin D metabolites. OBJECTIVE: Our goal was to determine if rifampin, a potent inducer of CYP3A4, can normalize mineral metabolism in patients with IIH due to mutations in CYP24A1. METHODS: We treated two patients with IIH with daily rifampin (10 mg/kg/d, up to a maximum of 600 mg). Serum calcium, phosphorus, parathyroid hormone (PTH), liver, and adrenal function and vitamin D metabolites, as well as urinary calcium excretion, were monitored during treatment of up to 13 months. RESULTS: Prior to treatment, both patients had hypercalcemia, hypercalciuria, and nephrocalcinosis with elevated serum 1,25-dihydroxyvitamin D3 and suppressed serum PTH. Daily treatment with rifampin was well tolerated and led to normalization or improvement in all clinical and biochemical parameters. CONCLUSION: These observations suggest that rifampin-induced overexpression of CYP3A4 provides an alternative pathway for inactivation of vitamin D metabolites in patients who lack CYP24A1 function.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Hawkes CP, Li D, Hakonarson H, et al. CYP3A4 Induction by Rifampin: An Alternative Pathway for Vitamin D Inactivation in Patients With CYP24A1 Mutations. J Clin Endocrinol Metab. 2017. PMID: 28324001. doi:10.1210/jc.2016-4048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。